Amgen Inc. $AMGN Stock: Sumitomo Mitsui Financial Group Inc. Raises Position

Sumitomo Mitsui Financial Group Inc. increased its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.6% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 85,661 shares of the medical research company’s stock after buying an additional 2,141 shares during the quarter. Amgen comprises approximately 0.6% of Sumitomo Mitsui Financial Group Inc.’s portfolio, making the stock its 29th biggest position. Sumitomo Mitsui Financial Group Inc.’s holdings in Amgen were worth $36,107,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of AMGN. Cornerstone Select Advisors LLC boosted its position in Amgen by 4.8% in the third quarter. Cornerstone Select Advisors LLC now owns 4,971 shares of the medical research company’s stock worth $2,096,000 after purchasing an additional 228 shares during the last quarter. Fort Sheridan Advisors LLC boosted its holdings in Amgen by 1.7% in the 3rd quarter. Fort Sheridan Advisors LLC now owns 8,653 shares of the medical research company’s stock worth $3,647,000 after buying an additional 148 shares during the period. E Fund Management Hong Kong Co. Ltd. grew its position in shares of Amgen by 52.3% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 4,763 shares of the medical research company’s stock worth $2,008,000 after purchasing an additional 1,636 shares in the last quarter. Sumitomo Life Insurance Co. grew its holdings in Amgen by 1.2% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 5,162 shares of the medical research company’s stock valued at $2,176,000 after buying an additional 63 shares in the last quarter. Finally, FCA Corp TX increased its holdings in Amgen by 2.2% in the 3rd quarter. FCA Corp TX now owns 16,602 shares of the medical research company’s stock valued at $6,998,000 after acquiring an additional 357 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of research reports. Truist Financial lifted their price objective on Amgen from $380.00 to $398.00 and gave the stock a “hold” rating in a research note on Wednesday, November 4th. Citigroup boosted their target price on Amgen from $405.00 to $465.00 and gave the company a “neutral” rating in a research report on Wednesday, November 4th. Robert W. Baird upped their price target on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Royal Bank Of Canada increased their price target on Amgen from $430.00 to $470.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 4th. Finally, Cantor Fitzgerald boosted their price objective on shares of Amgen from $440.00 to $465.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and an average target price of $428.62.

View Our Latest Analysis on AMGN

Amgen Price Performance

Shares of AMGN opened at $435.52 on Friday. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. Amgen Inc. has a 1-year low of $312.39 and a 1-year high of $483.99. The firm has a market capitalization of $235.58 billion, a PE ratio of 25.26, a price-to-earnings-growth ratio of 3.22 and a beta of 0.43. The company’s fifty day moving average price is $430.44 and its 200-day moving average price is $383.81.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The firm had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. During the same quarter in the prior year, the firm earned $5.64 earnings per share. Amgen’s revenue for the quarter was up 8.5% on a year-over-year basis. On average, equities research analysts predict that Amgen Inc. will post 23.41 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen’s payout ratio is presently 58.47%.

Amgen Profile

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Further Reading

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.